These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16423429)

  • 21. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.
    Madhi SA; Klugman KP; Kuwanda L; Cutland C; Käyhty H; Adrian P
    J Infect Dis; 2009 Apr; 199(8):1168-76. PubMed ID: 19265481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opsonic function of bronchoalveolar lavage IgG after pneumococcal vaccination in HIV-infected and uninfected adults.
    Tam JC; Grant NL; Freire-Moran L; Tolmie H; French N; Gordon SB
    J Allergy Clin Immunol; 2009 Jun; 123(6):1420-1. PubMed ID: 19423153
    [No Abstract]   [Full Text] [Related]  

  • 24. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological responses to pneumococcal vaccine in frail older people.
    Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
    Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
    Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
    Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of immunologic parameters and HIV RNA in relation to humoral pneumococcal polysaccharide vaccine responses in patients with HIV infection.
    Kvale D; Aaberge IS; Frøland SS
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):688-90. PubMed ID: 12373505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
    Almeida Vde C; Mussi-Pinhata MM; De Souza CB; Kubo CA; Martinez EZ; Carneiro-Sampaio MM; Duarte G
    Vaccine; 2009 Jun; 27(29):3856-61. PubMed ID: 19443091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunological effect of vaccination against pneumococcal infection in HIV-infected children].
    Pakhomov DV; Kostinov MP; Poddubikov AV; Vaneeva NP; Snegova NF; Nikitina TN; Zinkina TN; Suloeva SV
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):48-52. PubMed ID: 19459477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.
    Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Kim WJ
    Hum Vaccin Immunother; 2020; 16(1):169-175. PubMed ID: 31441710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization.
    Cohen AL; Harrison LH; Farley MM; Reingold AL; Hadler J; Schaffner W; Lynfield R; Thomas AR; Campsmith M; Li J; Schuchat A; Moore MR;
    AIDS; 2010 Sep; 24(14):2253-62. PubMed ID: 20671543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.